Frequently Asked Questions

Yes, accelRare is pre-diagnosis tool for healthcare professionals only, in priority for the primary care network, to help them to confirm the suspicion of a possible rare disease and speed up the referral of their patients to the appropriate expert center to confirm the diagnosis .

accelRare's ambition is to become the best in class digital companion in the pre-diagnosis of rare diseases for healthcare professionals.

medvir is based on validated scientific data.

- Orphadata from Orphanet: A best in class online database on rare diseases and orphan drugs.
Available on the site http://www.orphadata.org
© INSERM 1999 - January 2022 data release.
- Scientific literature publications.

All these data have been interpreted to be integrated into medvir.

100% of the rare diseases managed within accelRare have been reviewed by 50 experts in order to:

• Specify the entry signs of the disease,

• Ajust the frequency of those signs,

• Enrich the list of medical exams & medical histories,

• Specify the combinations of signs that should suggest the disease.

accelRare uses the pre-diagnostic & differential diagnosis tool medvir which is a reliable and robust "symptom checker" having 14 years of usage. All the results can be explained, allowing to provide easily an answer to any question from an health authority or a complaint.

medvir algorithm does not learn from source data (machine learning).

A study to assess accelRare's performance is currently on going, leading by the Digital Medical Hub (AP HP - France).

It is a simulation study (panel of common and rare diseases), randomized & comparative (doctors with accelRare versus doctors without accelRare).

The results of this study will be available early 2025.

A pilot performance study has already been performed in Q4 2023 to confirm the primary & secondary objectives.

accelRare does not save any data at the end of a pre-diagnosis.
If you wish, you can generate a PDF of the case studied in order to attach it to your patient file.

The questionnaire is 100% anonymous and secure.
Only the age and the gender of the patient are requested to refine the hypotheses related to this population.


accelRare complies with all personal data protection regulations. (See the terms of use in the footer).

accelRare/Medvir manages 225 symptoms, which can be expressed through a glossary of more than 20 000 words and expressions.
First try to enter this symptom with another synonym.

If you still can't find it, please send us an eMail:
- Either by the "Contact us" feature available in the footer of the solution,
- Either directly from your eMail messaging tool to the following address: accelRare.technicalsupport@sanofi.com.

Have you selected the main symptom from the list of symptoms you have completed?
To do it, you just have to click on the targeted symptom. A thumbtack will then appear in front of its name.
Just after, you will be able to move to the next step.

It is currently not possible to go back, nor to use the "Back" key of your internet browser, in this 1st accelRare's version.
This feature will be available early 2025.

The strength of accelRare is to suspect a rare disease, even from weak signals.

Today, accelRare can already suspect 270 rare diseases among the 7,000 identified so far, provided that you take time to answer all the questions asked during the questionnaire.
Now, your patient can also suffer from one of the 6,700 rare diseases that are not yet integrated into accelRare.

accelRare does not require a login and does not save any data at the end of a pre-diagnosis.
It is therefore impossible to regenerate a PDF when the user session is not longer active.

We invite you to re-complete the online questionnaire.

We are open to all improvements suggestions. Please send us an email:
- Either by the "Contact us" feature available in the footer of the solution,
- Either directly from your eMail messaging tool to the following address: accelRare.technicalsupport@sanofi.com.